HC Wainwright reissued their buy rating on shares of Check Cap (NASDAQ:CHEK) in a research note released on Wednesday, AnalystRatings.com reports. They currently have a $15.00 target price on the medical research company’s stock.
“We have assessed Y-mAbs using a discounted cash flow (DCF)-based methodology, which yields a total enterprise value of $1.45B. We utilize a 90% probability of approval for naxitamab in r/r neuroblastoma and for omburtamab in CNS mets from neuroblastoma. We utilize a 60% probability of approval for omburtamab in DIPG. Our discount rate is 10% and effective tax rate is 27.5%. We derive a market value of the firm of roughly $1.45B, which translates into a price per share of $40 assuming 37.8M shares outstanding as of end-1Q20.”,” HC Wainwright’s analyst commented.
Separately, Zacks Investment Research upgraded shares of HANNOVER RUECK/S from a sell rating to a hold rating in a research note on Friday, May 17th.
Check Cap (NASDAQ:CHEK) last announced its quarterly earnings results on Monday, May 13th. The medical research company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.03. As a group, analysts expect that Check Cap will post -1.69 earnings per share for the current year.
About Check Cap
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.
Further Reading: Correction
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.